Obstructive sleep apnea (OSA) is biologically heterogeneous, and distinct phenotypes show different treatment responses and adherence patterns. The current uniform, AHI‑driven care is misaligned with how the disease actually presents in many patients.
What happens when a therapy meets every regulatory requirement, but still isn’t covered? In sleep medicine, this is no longer an exception. It is a pattern. Devices can be FDA-cleared, clinically validated and fully coded, yet remain out of reach for patients due to fragmented and inconsistent payer policies.
